ClinicalTrials.gg
CompletedNCT06386744Updated Aug 26, 2026Results posted

Dusquetide for the Treatment of Behcet's Disease

A Phase 2 interventional study of Dusquetide in Behçet Disease, sponsored by Soligenix. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Soligenix · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Behcet Syndrome with a site in Turkey — 9 open to participants now, 10 under way, 3 of them phase 3. Behcet Syndrome · Turkey.

Enrollment
15th of 16
8 · median 83
Started
2024
with 3 others
Phase 2
5 of 30
none open now
Registered
24th of 30
by date

Among the 30 studies in Behcet Syndrome with a site in Turkey, this one is the 15th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2024, is one of 5 in phase 2, and was the 24th registered.

Behcet Syndrome

136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.

Browse Behcet Syndrome studies →

Open to participants now

9 of the 30 studies in Behcet Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Behcet Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

This is a clinical study to see if dusquetide can treat flares of oral and genital ulcers caused by Behcet's Disease. Study participants will receive an infusion of dusquetide twice a week for 4 weeks (8 treatments total), with weekly follow-up visits for an additional 4 weeks.

03

Conditions studied

  • Behçet Disease

Browse trials for

Keywords

  • dusquetide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a clinical diagnosis of Behcet's Disease meeting the International Study Group criteria.
  • Participants must have at least two oral ulcers and/or one genital ulcer on the day of randomization.
  • Participants willing to follow the clinical protocol and voluntarily give their written .
  • Female participants not pregnant or nursing and willing to undergo a pregnancy test prior to treatment initiation and at the end of the treatment period.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or mothers who are breast-feeding.
  • All women of (WOCBP) and males with female partners who are WOCBP not willing to agree to the use of effective during the trial.
  • Evidence of significant renal, hepatic, hematologic or immunologic disease.
  • Use of any medication within 4 weeks prior to enrollment or 5 pharmacokinetic/pharmacodynamic half-lives (whichever is longer).
  • Having received concomitant immune modulating therapy (except colchicine) within:

    1. Ten days prior to enrollment for azathioprine and mycophenolate mofetil,
    2. Four weeks (28 days) prior to enrollment for cyclosporine, methotrexate, cyclophosphamide, thalidomide and dapsone
    3. Oral and topical must have been tapered as appropriate and discontinued 3 days prior to day of enrollment
    4. At least 5 terminal half-lives for all biologics including, but not limited to, those listed below; within: i. Four weeks prior to enrollment for etanercept; ii. Eight weeks prior to enrollment for infliximab; iii. Ten weeks prior to enrollment for adalimumab, golimumab, certolizumab, abatacept, and tocilizumab; iv. Six months prior to enrollment for secukinumab.
  • Having received oral or parenteral corticosteroids within 6 weeks (42 days) prior to enrollment.
  • Having received apremilast (Otezla) within 4 weeks prior to enrollment.
  • Presence of non- Behcet's Disease related genital ulcers, including both infectious and non-infectious etiologies.
  • Active organ involvement requiring treatment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    SGX945

    This is an open-label study and all participants will receive SGX945.

    Drug: Dusquetide

Interventions

  • 1.5 mg/mL dusquetide administered as a 4 minute IV infusion, twice per week for 4 weeks

    Also known as: SGX945, SGX942

06

What researchers measure

Primary outcomes

  1. Number of Oral Ulcers

    The number of oral ulcers were counted at baseline and each visit during the treatment period.

    Time frame: 4 weeks

  2. Number of Genital Ulcers

    The number of genital ulcers will be counted at baseline and each visit during the treatment period.

    Time frame: 4 weeks

Secondary outcomes

  1. Change in Pain of Oral Ulcers From Baseline to End of Treatment

    The pain of oral ulcers was measured using a 100 mm Visual Analog Scale (VAS) at baseline and each visit during the treatment period. The minimum score is 0 mm (no pain) and the maximum score is 100 mm (maximum pain). The change in pain is the difference between the score at baseline and the score at the end of treatment, where a negative value indicates a reduction in pain.

    Time frame: 4 weeks

  2. Change in Pain of Genital Ulcers From Baseline to End of Treatment

    The pain of genital ulcers was measured using a 100 mm Visual Analog Scale (VAS) at baseline and each visit during the treatment period. The minimum score is 0 mm (no pain) and the maximum score is 100 mm (maximum pain). The change in pain is the difference between the score at baseline and the score at the end of treatment, where a negative value indicates a reduction in pain.

    Time frame: 4 weeks

07

Results

Posted Aug 26, 2026

Participant flow

Participant flow — Overall Study
MilestoneSGX945
Started8
Completed8
Not completed0

Outcome measures

PrimaryNumber of Oral Ulcers

The number of oral ulcers were counted at baseline and each visit during the treatment period.

Time frame:
4 weeks
Reported as:
Mean · Oral Ulcers
Number of Oral Ulcers
Oral UlcersSGX945
Baseline2.9 (2 to 5)
End of Treatment1.6 (-0.4 to 3.6)
SecondaryChange in Pain of Oral Ulcers From Baseline to End of Treatment

The pain of oral ulcers was measured using a 100 mm Visual Analog Scale (VAS) at baseline and each visit during the treatment period. The minimum score is 0 mm (no pain) and the maximum score is 100 mm (maximum pain). The change in pain is the difference between the score at baseline and the score at the end of treatment, where a negative value indicates a reduction in pain.

Time frame:
4 weeks
Reported as:
Mean · scores on a scale
Change in Pain of Oral Ulcers From Baseline to End of Treatment
scores on a scaleSGX945
Change in Pain of Oral Ulcers From Baseline to End of Treatment-47 (-78.3 to -16.5)
SecondaryChange in Pain of Genital Ulcers From Baseline to End of Treatment

The pain of genital ulcers was measured using a 100 mm Visual Analog Scale (VAS) at baseline and each visit during the treatment period. The minimum score is 0 mm (no pain) and the maximum score is 100 mm (maximum pain). The change in pain is the difference between the score at baseline and the score at the end of treatment, where a negative value indicates a reduction in pain.

Time frame:
4 weeks
Reported as:
Mean · scores on a scale

No measurements were reported for this outcome.

PrimaryNumber of Genital Ulcers

The number of genital ulcers will be counted at baseline and each visit during the treatment period.

Time frame:
4 weeks
Reported as:
Mean · Genital Ulcers
Number of Genital Ulcers
Genital UlcersSGX945
Baseline0 (0 to 0)
End of Treatment0 (0 to 0)

Adverse events

Collected over From enrollment until end of follow-up, up to 8 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SGX9450/8 (0%)0/8 (0%)7/8 (87.5%)
Most frequent other events
Most frequent other events
EventSGX945
Upper respiratory tract infectionInfections and infestations2/8
Administration site extravasationGeneral disorders1/8
Peripheral swellingGeneral disorders1/8
Tinnea infectionInfections and infestations1/8
Pain in extremityMusculoskeletal and connective tissue disorders1/8
ArthralgiaMusculoskeletal and connective tissue disorders1/8
Sinus bradycardiaCardiac disorders1/8
HeadacheNervous system disorders1/8
MaculeSkin and subcutaneous tissue disorders1/8
HypertensionVascular disorders1/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)SGX945
Mean43 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)SGX945
Female6
Male2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SGX945
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White8
More than one race0
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SGX945
Caucasian8
Region of Enrollment
Region of Enrollment(Participants)SGX945
Turkey8
08

Study locations

1 site
  • Istanbul University - Cerrahpasa, Cerrahpasa School of Medicine
    Istanbul, Turkey (Türkiye)
09

References and documents

Publications

  • Donini O, Sulu B, Pullion C, Rumage A, Straube R, Schaber C, Hatemi G. Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behcet's syndrome. Rheumatology (Oxford). 2026 Feb 4;65(2):keaf682. doi: 10.1093/rheumatology/keaf682. PubMed 41400947 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in May 2025, 6 months.

Results were first posted in Aug 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2024
First posted
Apr 26, 2024
StartActual
Nov 18, 2024
Primary completionActual
May 23, 2025
CompletionActual
Jun 17, 2025
Results first posted
Aug 26, 2026
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06386744
Lead sponsor
Soligenix
Responsible party
Sponsor
First posted
Apr 26, 2024
Start date
Nov 18, 2024
Primary completion
May 23, 2025
Completion
Jun 17, 2025
Results posted
Aug 26, 2026
Last update
Aug 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dusquetide

Start the discussion